Labcorp

Current directors and officers who also hold a role at another S&P 500 company.

• Adam H. SchechterDVA · Director
• Jeffrey A. DavisFDXF · Director
• Kathryn E. WengelJNJ · Officer
• Kerrii B. AndersonSHW · Director
• Kirsten Marie KliphouseGPN · Director
• Paul RothmanMRK · Director
• Richelle P. ParhamBBY · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Aug 14, 2026

   On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses.

   Read the 8-K filing
2. Feb 9, 2026

   Labcorp Holdings Inc. (the “Company”) today announced that on February 6, 2026, the Company’s Board of Directors (the “Board”) appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson’s appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company’s director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. Before joining the CU Anschutz School of Medicine, Dr.

   Read the 8-K filing
3. Dec 15, 2025

   On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the “Company”), notified the Company of his intention to retire, effective on April 1, 2026.

   Read the 8-K filing
4. Dec 10, 2025

   On December 5, 2025, Dr. D. Gary Gilliland notified the Board of Directors (the “Board”) of Labcorp Holdings Inc. (the “Company”) of his decision to retire from the Board, effective December 31, 2025.

   Read the 8-K filing
5. Nov 24, 2025

   Labcorp Holdings Inc. (the “Company”) today announced that on November 20, 2025, the Company’s Board of Directors (the “Board”) appointed Victor Bulto as a member of the Board, effective December 1, 2025. Mr. Bulto will be entitled to receive compensation for his service on the Board consistent with the Company’s director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025. Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in each role since April 2022. In his more than two decades of experience at Novartis, Mr. Bulto has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr.

   Read the 8-K filing
6. May 20, 2025

   On May 15, 2025, the shareholders of Labcorp Holdings Inc. (the “Company”) approved the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan (the “2025 Omnibus Incentive Plan”) and the Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan (the “2025 ESPP”) at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”). Descriptions of the 2025 Omnibus Incentive Plan and the 2025 ESPP are set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2025 (the “Proxy Statement”), in the sections entitled “Proposal Three: Vote to Approve 2025 Omnibus Incentive Plan” and “Proposal Four: Vote to Approve the 2025 Employee Stock Purchase Plan”, respectively, which are incorporated into this Current Report by reference.

   Read the 8-K filing
7. Nov 19, 2024

   On November 19, 2024, Labcorp Holdings Inc. (“Labcorp”) announced that on November 15, 2024, Glenn Eisenberg notified Labcorp of his intention to retire from Labcorp effective April 30, 2025. Labcorp also announced that Julia Wang, age 54, was appointed to the position of Executive Vice President and Chief Financial Officer (“CFO”). Mr. Eisenberg will step down from his role as Labcorp’s Executive Vice President and Chief Financial Officer effective December 2, 2024 (the “Transition Date”) in order to support the effective transition to Julia Wang of the CFO role on the Transition Date. From the Transition Date through the date of his retirement, Mr. Eisenberg will assume the role of Special Advisor to Labcorp’s Chief Executive Officer, working on the transition of his current role and assisting with strategic initiatives underway within Labcorp. Prior to joining Labcorp, Ms.

   Read the 8-K filing
8. Sep 11, 2023

   As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other opportunities. Labcorp announced today that on September 8, 2023, Labcorp and Dr. Kirchgraber agreed that he would resign as an executive officer and employee of Labcorp effective on September 1, 2023 (the “Separation Date”) and that his departure would be treated as a resignation for “good reason” for purposes of Labcorp’s Amended and Restated Master Senior Executive Severance Plan (the “Severance Plan”). Under the terms of the Severance Plan, Dr.

   Read the 8-K filing
9. Jun 7, 2023

   Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023. Dr. Rothman will be entitled to receive compensation for his service on the Board consistent with Labcorp’s director compensation program, as described in Labcorp's most recent proxy statement, filed with the Securities and Exchange Commission on March 30, 2023. Dr. Rothman, a rheumatologist and molecular immunologist, recently retired after a decade as the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr.

   Read the 8-K filing
10. May 5, 2023

    In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Labcorp, on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023. In connection with Dr. Caveney’s appointment, his base salary was increased to $650,000 and on May 5, 2023 he received a restricted stock unit award and a stock option award, each with a value of $67,000, and a performance share award with a value of $201,000.

    Read the 8-K filing
11. May 5, 2023

    In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Labcorp, on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023. In connection with Mr. Schroeder’s appointment, his base salary was increased to $650,000 and on May 5, 2023, he received a restricted stock unit award and a stock option award, each with a value of $100,000, and a performance share award with a value of $300,000.

    Read the 8-K filing
12. May 4, 2023

    In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Laboratory Corporation of America ® Holdings (“Labcorp”), on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023. In connection with Mr. Schroeder’s appointment, his base salary was increased to $650,000, and on May 5, 2023, he will receive a restricted stock unit award and a performance share award, each with a value of $100,000, and a stock option award with a value of $300,000.

    Read the 8-K filing
13. May 4, 2023

    In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Laboratory Corporation of America ® Holdings (“Labcorp”), on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023. In connection with Dr. Caveney’s appointment, his base salary was increased to $650,000 and on May 5, 2023, he will receive a restricted stock unit award and a performance share award, each with a value of $67,000, and a stock option award with a value of $201,000.

    Read the 8-K filing
14. Jan 5, 2023

    On January 5, 2023, Laboratory Corporation of America® Holdings (“Labcorp”) announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023 (the “Effective Date”), and, upon completion of the previously announced planned spin-off of Labcorp’s Clinical Development business, Mr. Pike will become chief executive officer and chairman of the Board of Directors of the spun-off company. Mr. Pike will report to Labcorp’s President, CEO and Chairman of the Board of Directors as of the Effective Date until completion of the spin-off. On January 4, 2023, Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.

    Read the 8-K filing
15. Oct 13, 2022

    Laboratory Corporation of America Holdings (“Labcorp”) today announced that on October 12, 2022, Labcorp’s Board of Directors (the “Board”) appointed Kirsten M. Kliphouse as a member of the Board, effective immediately. Ms. Kliphouse will be entitled to receive compensation for her service on the Board consistent with Labcorp’s director compensation program, as described in Labcorp's most recent proxy statement, filed with the Securities and Exchange Commission on March 31, 2022. Ms. Kliphouse currently serves as President of Americas of Google Cloud and previously served as President of North America of Google Cloud since June 2019. Ms.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.